1993 Fiscal Year Final Research Report Summary
A new approach to arterial and portal chemoembolization therapy for unresectable hepatocellular carcinoma
| Project/Area Number |
04670791
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kumamoto university medical school |
|---|
Principal Investigator |
KATAFUCHI Shigeru Kumamoto university medical school, Department of Surgery II, reserch associate, 医学部, 助手 (50233747)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IKEI Satoshi Kumamoto university medical school, Department of Surgery II, assistant professo, 医学部, 講師 (90136705)
OGAWA Michio Kumamoto university medical school, Department of Surgery II, professor, 医学部, 教授 (30028691)
|
|---|
| Project Period (FY) |
1992 – 1993
|
| Keywords | Percutaneous transhepatic portal chemoembolization (PTPCE) / Transcatheter arterial chemoembolization (TACE) / Cisplatin suspended in lipiodol(CSL)-fibrin adhesive mixture / Hepatocellular carcinoma (HCC) / Chemoembolization |
|---|
| Research Abstract |
We developed cisplatin suspended in lipiodol (CSL)-fibrin adhesive mixture as a new embolic material in arterial and portal chemoembolization therapy for unresectable hepatocellular carcinoma (HCC).
Experimental study
A rat HCC model was made by intraportal inoculation of AH136B rat ascites hepatoma cell. Percutaneous transhepatic portal chemoembolization (PTPCE) performed 4 days after the cell inoculation, resulted in prolonging the survival time, inhibiting the tumor growth, and suppressing the intrahepatic metastasis in comparison with control animals.
Clinical data
We treated twelve patients with HCC by PTPCE in combination with transcatheter arterial chemoembolization (TACE). PTPCE could be performed safely in all cases. According to response criteria, response rate was 66.7%. The cumulative survival rate at 2 years was 80.0%. In resectable cases after TACE/PTPCE, histological examination revealed necrotic changes of the main tumor and the portal embolus. There were no lethal side effects and complications through the study.
Conclusion
PTPCE in combination with TACE has exellent therapeutic effects not only for main tumor but also for portal or capsular invasion. PTPCE may become a useful tool in the treatment of unresectable HCC.
|
-
-
-
[Publications] T.Beppu, C.Ohara, Y.Yamaguchi, T.Yamanaka, S.Katafuchi, S.Ikei, S.Kudo, Y.Masuda, S.fukushima, M.Nakano, M.Ogawa: "A new chemoembolization therapy for unresectable hepatocellular carcinoma using Aclarubicin microspheres in combination with Cisplatin suspended in lipiodol." Reg.Cance Treat. 1-2. 33-35 (1992)
Description
「研究成果報告書概要(欧文)」より
-
[Publications] Satoshi Ikei, Michio Ogawa, Toru Beppu, Chitoshi Ohara, Kiyoshi Sakamoto, Hirofumi Sameshima, Hirohumi Arakawa, Yasuo Yamaguchi, Tsuyoshi Yamanaka, Shunsuke Kudou: "Changes in Interleukin 6, Interleukin 8, C-reactive Protein and Pancreatic Secretory Trypsin Inhibitor(PSTI) after Transcatheter Arterial Chemoembolization Therapy (TACE)." CYTOKINE. 4. 581-584 (1992)
Description
「研究成果報告書概要(欧文)」より
